Search

Ipsen SA.

Deschisă

SectorFinanțe

158 -1.25

Rezumat

Modificarea prețului

24h

Curent

Minim

159.6

Maxim

161.8

Indicatori cheie

By Trading Economics

Venit

294M

403M

Vânzări

334M

2.2B

P/E

Medie Sector

24.733

19.1

Randament dividend

0.96

Marjă de profit

18.405

Angajați

5,535

EBITDA

556M

1B

Recomandări

By TipRanks

Recomandări

Neutru

Prognoză pe 12 luni

+9.84% upside

Dividende

By Acuity

Randament dividend

Medie Sector

0.96%

4.56%

Statistici piață

By TradingEconomics

Capitalizare de piață

-465M

13B

Deschiderea anterioară

159.25

Închiderea anterioară

158

Sentimentul știrilor

By Acuity

43%

57%

139 / 438 Clasament în Finance

Ipsen SA. Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

8 aug. 2026, 00:06 UTC

Event
News

Abcellera Biologics will release Phase 2 trial results for ABCL635 on August 10, 2026. Shares are trading higher in after-market hours.

8 aug. 2026, 00:02 UTC

News

Eli Lilly shares are higher in after-market trading following FDA filing plans for retatrutide, a potential competitor in the weight-loss market.

8 aug. 2026, 00:02 UTC

Social Media
News

Cloudflare Inc. shares are trading higher after a strong earnings report, with revenue up 36% and upwardly revised full-year guidance. TD Cowen raised its price target to $355.

8 aug. 2026, 00:02 UTC

News

Celsius Holdings Inc shares are lower in after-market hours following an investigation into potential securities law violations and disappointing second-quarter revenue.

8 aug. 2026, 00:02 UTC

News

Dropbox shares are higher in after-hours trading following Citigroup's price target increase to $33, maintaining a Neutral rating on the stock.

8 aug. 2026, 00:01 UTC

News

Citigroup raised its price target for Cognex Corp to $74, maintaining a Neutral rating. Shares are higher in after-market hours, recovering from recent losses.

8 aug. 2026, 00:01 UTC

News

UBS raised its price target on Howmet Aerospace to $326. Shares are trading higher in after-market hours following the report.

8 aug. 2026, 00:01 UTC

News

Mitek Systems reported an 18% revenue increase in Q3, driven by strong SaaS growth. Shares rose after-market, settling higher since Friday's close.

7 aug. 2026, 23:56 UTC

News

Sweetgreen shares declined in after-market trading as multiple analysts lowered price targets, with UBS and RBC both setting targets at $6.50.

7 aug. 2026, 23:46 UTC

News

JetBlue Airways reports wider net loss and updates operating guidance. Shares are lower in after-market trading following the $121.4 million shelf registration.

7 aug. 2026, 23:46 UTC

News

Etsy Inc shares are lower in after-market hours following its Q2 results, which showed a double beat but faced revenue challenges from divestments.

7 aug. 2026, 23:46 UTC

News

Cogent Communications is trading lower in after-market hours amid a class action lawsuit alleging securities fraud by Pomerantz LLP and ongoing operational challenges.

7 aug. 2026, 23:41 UTC

News

ResMed shares declined after-market despite RBC Capital raising its price target to $244 and maintaining a Sector Perform rating.

7 aug. 2026, 23:41 UTC

News

Mitek Systems reported an 18% revenue increase in Q3, with shares advancing in after-market hours, despite earlier pulling back from a session high.

7 aug. 2026, 23:36 UTC

News

Tripadvisor Inc announced participation in two investor conferences, enhancing engagement with investors. Shares are trading slightly higher in after-market hours.

7 aug. 2026, 23:36 UTC

News

Shift4 Payments lowers 2026 outlook, adjusting full-year revenue guidance down by about 200 basis points. Shares are trading lower in after-market hours.

7 aug. 2026, 23:36 UTC

News

Epam Systems shares are trading lower in after-market hours following TD Cowen's price target cut to $120, despite earlier gains in the session.

7 aug. 2026, 23:31 UTC

News

Arcutis Biotherapeutics granted 143,500 RSUs and options to new hires. Shares are trading higher in after-market hours following the announcement.

7 aug. 2026, 23:31 UTC

News

Figs Inc reported strong Q2 earnings but is trading lower in after-market hours as Telsey Advisory Group lowered its price target to $16.

7 aug. 2026, 23:31 UTC

News

Ardelyx shares are higher in after-market trading as TD Cowen maintains a Buy rating and lowers the price target to $10.

7 aug. 2026, 23:31 UTC

News

Celsius Holdings is under investigation for potential securities law violations following disappointing second-quarter results, with shares trading lower in after-market hours.

7 aug. 2026, 23:26 UTC

News

Delta Air Lines is gaining after reporting strong second-quarter results and positive passenger traffic growth projections, with anticipated earnings of $6.63 per share.

7 aug. 2026, 23:26 UTC

News

Five9 Inc. reported second-quarter earnings of $0.70 per share and raised full-year revenue guidance to $1.27 billion. Shares are higher in after-market trading.

7 aug. 2026, 23:26 UTC

News

UBS raised its price target on Unity Software Inc. to $48, contributing to shares trading higher in after-market hours. Positive sentiment from tech stocks also supported this move.

7 aug. 2026, 23:26 UTC

Event
News

Scholar Rock Holding Corp reports FDA review progress for apitegromab, with a decision expected by September 30, 2026. Shares are trading higher in after-market hours.

7 aug. 2026, 23:26 UTC

News

Kraft Heinz Co reported second-quarter revenue of $6.26 billion, exceeding expectations. Shares rose in after-market trading amid positive sentiment and broader market strength.

7 aug. 2026, 23:26 UTC

News

Leidos Holdings shares are lower in after-market hours after TD Cowen raised the price target to $135 while maintaining a Hold rating.

7 aug. 2026, 23:21 UTC

News

MP Materials will participate in Canaccord Genuity's Growth Conference in August 2026. Shares are trading higher in after-market hours following the announcement.

7 aug. 2026, 23:21 UTC

News

TD Cowen raised its price target on Akamai Technologies to $140 while maintaining a Hold rating. Shares are higher in after-market trading.

7 aug. 2026, 23:21 UTC

Social Media
News
Event

Abcellera Biologics will release Phase 2 trial results for ABCL635 on August 10, 2026. Shares are sharply higher in after-market trading amid positive investor sentiment.

Comparație

Modificare preț

Ipsen SA. Așteptări

Obiectiv de preț

By TipRanks

9.84% sus

Prognoză pe 12 luni

Medie 177.5 EUR  9.84%

Maxim 235 EUR

Minim 135 EUR

În baza a 5 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruIpsen SA. - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Neutru

5 ratings

1

Cumpărare

3

Păstrare

1

Vânzare

Sentiment

By Acuity

139 / 438 Clasament în Finanțe

Sentimentul știrilor

Evidențe de creștere

Volatilitate

Sub medie

Volumul știrilor (RCV)

Sub medie

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

$

Despre Ipsen SA.

Ipsen S.A. operates as a biopharmaceutical company worldwide. The company provides drugs in the areas of oncology, neuroscience, and rare diseases. Its product pipeline comprises Cabometyx + Atezolizumab, which is in phase III clinical trial for the treatment of second line metastatic castration-resistant prostate cancer; lenalidomide and rituximab, and Taverik, which is in phase III for the treatment of second line follicular lymphoma; Bylvay, which is in phase III for the treatment of biliary atresia; Dysport, which is in phase III clinical trial for the treatment of chronic and episodic migraine; Fidrisertib, which is in phase II clinical trial for the treatment of fibrodysplasia ossificans progressiva; Elafibranor, which is in phase II for the treatment of primary sclerosing cholangitis, as well as IPN60250; IPN10200, which is in phase II for the treatment of longer-acting neurotoxin aesthetics and therapeutics; IPN60210, which is in phase I clinical trial for the treatment of relapsed/refractory multiple myeloma; and IPN60260 for the treatment of Viral cholestatic disease and is in phase I clinical trial. The company also offers Somatuline, Decapeptyl, Cabometyx, Onivyde, Tazverik, and other oncology products; Dysport and other neurosciences products; and Bylvay, NutropinAq, Increlex, and Sohonos for rare diseases. The company was founded in 1929 and is based in Boulogne-Billancourt, France.
help-icon Live chat